atorvastatin

(redirected from Liptruzet)
Also found in: Dictionary, Thesaurus.

atorvastatin

 [ah-tor″vah-stat´in]
an agent that inhibits cholesterol synthesis, used as the calcium salt in treatment of primary hypercholesterolemia and hyperlipidemia; administered orally.

atorvastatin

(ə-tôr′və-stăt′n)
n.
A statin, (C33H34FN2O5)2Ca·3H2O, that blocks the body's synthesis of cholesterol and is used to treat hyperlipidemia.

atorvastatin

A cholesterol-lowering HMG-CoA reductase inhibitor, or statin, which improves the lipid profile—LDL-C reduced 35% to 60%; TGs reduced 20–37%; HDL-C increased 5–9%.
 
Adverse effects
Liver dysfunction, rhabdomyolysis with acute renal failure secondary to myoglobinuria, constipation, flatulence, dyspepsia, abdominal pain, myalgia, weakness.
 
Indications
Homozygous familial hypercholesterolaemia, severe refractory hypercholesterolaemia.

atorvastatin

Lipitor® Cardiology A cholesterol-lowering HMG-CoA reductase inhibitor or statin which improves the lipid profile–↓ 35% to 60% LDL-C; ↓TGs 20–37%;↑ 5–9% HDL-C Adverse effects Liver dysfunction, rhabdomyolysis with acute renal failure 2º to myoglobinuria, constipation, flatulence, dyspepsia, abdominal pain, myalgia, weakness. See AVERT, Statin.

atorvastatin

A cholesterol-lowering drug. A brand name is Lipitor. See STATINS.
References in periodicals archive ?
LIPTRUZET (ezetimibe and atorvastatin) will be available for wholesalers to order in the week of 6 May 2013.
One analyst opined that the FDA would not have approved Liptruzet if there were indications of worrisome signs with the Improve-It trial.
And given that Merck needs to boost revenue, it is unlikely Liptruzet will offer a cost advantage, which means the pill will really offer no advantage at all.
Unlike so many other instances when a drug is approved, the agency this time did not release a statement explaining its rationale for endorsing Liptruzet. This was a classic instance in which the lack of explanation allowed criticism to fill the void--and the criticism was stinging.
Instead, the Liptruzet approval has now prompted speculation that the agency has become too concerned with a "numbers game," reflecting increased pressure from the pharma industry and its allies in Congress, who expect to see tangible results for the increased user fees that drug makers pay each year for the drug review process.
The agency had a regulatory obligation to review Liptruzet and the pill, presumably, passed the necessary hurdles.
(Yes, that was another Merck drug.) Since then, the FDA has worked hard to restore its image as a worthy watchdog, but the Liptruzet approval may erode any perceived gains.